Unknown

Dataset Information

0

Atorvastatin added to interferon ? for relapsing multiple sclerosis: a randomized controlled trial.


ABSTRACT: Statins have anti-inflammatory and immunomodulatory properties in addition to lipid-lowering effects. The present study evaluated the effect of atorvastatin added to interferon beta-1b in multiple sclerosis (MS) in a multicenter, randomized, parallel-group, rater-blinded study performed in eight Swiss hospitals. Seventy-seven patients with relapsing-remitting MS started interferon beta-1b every other day. After 3 months, they were randomized 1:1 to receive atorvastatin 40 mg/day or not in addition to interferon beta-1b until month 15. The primary endpoint was the proportion of patients with new lesions on T2-weighted images at month 15 compared to baseline at month three. At study end, the proportion of patients with new lesions on T2-weighted images was equal in both groups (odds ratio 1.14; 95 % CI 0.36-3.56; p = 0.81). All predefined secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of new Gd-enhancing lesions on T1-weighted images, total brain volume, volume of grey matter, volume of white matter, EDSS, MSFC, relapse rate, time to first relapse, number of relapse-free patients and neutralizing antibodies did not show any significant differences (all p values >0.1). Transient elevations of liver enzymes were more frequent with atorvastatin (p = 0.02). In conclusion, atorvastatin 40 mg/day in addition to interferon beta-1b did not have a beneficial effect on relapsing-remitting MS compared to interferon beta-1b monotherapy over a 12-month period.

SUBMITTER: Kamm CP 

PROVIDER: S-EPMC3484273 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


Statins have anti-inflammatory and immunomodulatory properties in addition to lipid-lowering effects. The present study evaluated the effect of atorvastatin added to interferon beta-1b in multiple sclerosis (MS) in a multicenter, randomized, parallel-group, rater-blinded study performed in eight Swiss hospitals. Seventy-seven patients with relapsing-remitting MS started interferon beta-1b every other day. After 3 months, they were randomized 1:1 to receive atorvastatin 40 mg/day or not in additi  ...[more]

Similar Datasets

| S-EPMC3907426 | biostudies-literature
| S-EPMC8054966 | biostudies-literature
| S-EPMC7296452 | biostudies-literature
| S-EPMC2276246 | biostudies-literature
| S-EPMC4431469 | biostudies-literature
| S-EPMC4234663 | biostudies-literature
| S-EPMC5400152 | biostudies-literature
| S-EPMC9421448 | biostudies-literature
| S-EPMC5805817 | biostudies-other
| S-EPMC6400872 | biostudies-literature